Monday, May 20, 2013
Galileo Research S.r.L's allogeneic stem cell therapy mimics natural killer
cells to stimulate tumor cell apoptosis, but does not attack healthy cells. The
off-the-shelf therapy could have broader activity against cancer than
allogeneic vaccines in development. But first, the biotech needs to raise
$8-$10 million to support a Phase II trial in advanced ovarian cancer.
Galileo's TALL-104 is an
irradiated, non-proliferating, clonal T cell line, with MHC non-restricted
killer cell activity against tumors.